دورية أكاديمية
أعرض في EDS

GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach

التفاصيل البيبلوغرافية
العنوان: GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach
المؤلفون: CRISCI, ISABELLA, Aragona, Michele, Politi, Konstantina Savvina, DANIELE, GIUSEPPE, DEL PRATO, STEFANO
المساهمون: Crisci, Isabella, Aragona, Michele, Politi, Konstantina Savvina, Daniele, Giuseppe, DEL PRATO, Stefano
سنة النشر: 2015
المجموعة: ARPI - Archivio della Ricerca dell'Università di Pisa
مصطلحات موضوعية: Continuous glucose monitoring, Glycemic variability, Insulin pump therapy, Liraglutide, Type 1 diabete, Adult, Aged, Area Under Curve, Blood Glucose, Body Mass Index, C-Peptide, Diabetes Mellitus, Type 1, Female, Glucagon-Like Peptide-1 Receptor, Hemoglobin A, Glycosylated, Human, Hypoglycemia, Hypoglycemic Agent, Male, Middle Aged, Endocrinology, Internal Medicine, Diabetes and Metabolism
الوصف: Aims: To test potential efficacy of liraglutide, a GLP-1 receptor agonist, in subjects with type 1 diabetes (T1DM). Methods: We have recruited nine T1DM patients (age 40.1±6.4years, duration of diabetes 19.2±8.8years, BMI 24.3±3.5kg/m2, HbA1c 8.2±1.0%–66±11mmol/mol, daily insulin dose: 0.6±0.1IU/kg) on continuous subcutaneous insulin therapy with undetectable C-peptide. In addition to existing treatment was administered in single-blind (a) therapy subcutaneously with 0.1ml of saline solution for 3days and (b) 0.1ml of liraglutide (0.6mg/day) for a further 3days with daily glucose excursions recorded by continuous glucose monitoring. Results: Adding liraglutide resulted in a significant reduction in mean blood glucose (138±29 vs. 163±29mg/dl, p<0.0001) and standard deviation (42±9 vs. 60±15mg/dl, p<0.0001). The area under the curve (AUC) for blood glucose >140mg/dl was also significantly reduced (22.2±16.4 vs. 41.1±19.7mg/dlh, p<0.05) with no difference in AUC for blood glucose <70mg/dl (liraglutide 0.7±0.9mg/dlh; placebo: 0.8±1.4mg/dlh, p=NS). Finally, adding liraglutide reduced daily insulin requirement (37.5±17.2 vs. 42.9±22.4 UI/day, p<0.01). Conclusions: Short-term treatment with liraglutide, in T1DM, reduces average blood glucose, blood glucose variability and daily insulin requirement without increasing risk of hypoglycemia.
نوع الوثيقة: article in journal/newspaper
وصف الملف: STAMPA
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26293127; info:eu-repo/semantics/altIdentifier/wos/WOS:000363950500014; volume:52; issue:6; firstpage:1129; lastpage:1133; numberofpages:5; journal:ACTA DIABETOLOGICA; http://hdl.handle.net/11568/763653Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84945461146; link.springer.de/link/service/journals/00592/index.htm
DOI: 10.1007/s00592-015-0800-6
الإتاحة: https://doi.org/10.1007/s00592-015-0800-6Test
http://hdl.handle.net/11568/763653Test
رقم الانضمام: edsbas.470545AE
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.470545AE
792
3
Academic Journal
academicJournal
792.1474609375
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.470545AE&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doi.org/10.1007/s00592-015-0800-6# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22CRISCI%2C+ISABELLA%22&quot;&gt;CRISCI, ISABELLA&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Aragona%2C+Michele%22&quot;&gt;Aragona, Michele&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Politi%2C+Konstantina+Savvina%22&quot;&gt;Politi, Konstantina Savvina&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22DANIELE%2C+GIUSEPPE%22&quot;&gt;DANIELE, GIUSEPPE&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22DEL+PRATO%2C+STEFANO%22&quot;&gt;DEL PRATO, STEFANO&lt;/searchLink&gt; )
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Crisci, Isabella&lt;br /&gt;Aragona, Michele&lt;br /&gt;Politi, Konstantina Savvina&lt;br /&gt;Daniele, Giuseppe&lt;br /&gt;DEL PRATO, Stefano )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2015 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => ARPI - Archivio della Ricerca dell&#39;Universit&#224; di Pisa )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Continuous+glucose+monitoring%22&quot;&gt;Continuous glucose monitoring&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Glycemic+variability%22&quot;&gt;Glycemic variability&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Insulin+pump+therapy%22&quot;&gt;Insulin pump therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Liraglutide%22&quot;&gt;Liraglutide&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Type+1+diabete%22&quot;&gt;Type 1 diabete&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Adult%22&quot;&gt;Adult&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Aged%22&quot;&gt;Aged&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Area+Under+Curve%22&quot;&gt;Area Under Curve&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Blood+Glucose%22&quot;&gt;Blood Glucose&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Body+Mass+Index%22&quot;&gt;Body Mass Index&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22C-Peptide%22&quot;&gt;C-Peptide&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Diabetes+Mellitus%22&quot;&gt;Diabetes Mellitus&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Type+1%22&quot;&gt;Type 1&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Female%22&quot;&gt;Female&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Glucagon-Like+Peptide-1+Receptor%22&quot;&gt;Glucagon-Like Peptide-1 Receptor&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Hemoglobin+A%22&quot;&gt;Hemoglobin A&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Glycosylated%22&quot;&gt;Glycosylated&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Human%22&quot;&gt;Human&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Hypoglycemia%22&quot;&gt;Hypoglycemia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Hypoglycemic+Agent%22&quot;&gt;Hypoglycemic Agent&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Male%22&quot;&gt;Male&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Middle+Aged%22&quot;&gt;Middle Aged&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Endocrinology%22&quot;&gt;Endocrinology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Internal+Medicine%22&quot;&gt;Internal Medicine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Diabetes+and+Metabolism%22&quot;&gt;Diabetes and Metabolism&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Aims: To test potential efficacy of liraglutide, a GLP-1 receptor agonist, in subjects with type 1 diabetes (T1DM). Methods: We have recruited nine T1DM patients (age 40.1&#177;6.4years, duration of diabetes 19.2&#177;8.8years, BMI 24.3&#177;3.5kg/m2, HbA1c 8.2&#177;1.0%–66&#177;11mmol/mol, daily insulin dose: 0.6&#177;0.1IU/kg) on continuous subcutaneous insulin therapy with undetectable C-peptide. In addition to existing treatment was administered in single-blind (a) therapy subcutaneously with 0.1ml of saline solution for 3days and (b) 0.1ml of liraglutide (0.6mg/day) for a further 3days with daily glucose excursions recorded by continuous glucose monitoring. Results: Adding liraglutide resulted in a significant reduction in mean blood glucose (138&#177;29 vs. 163&#177;29mg/dl, p&lt;0.0001) and standard deviation (42&#177;9 vs. 60&#177;15mg/dl, p&lt;0.0001). The area under the curve (AUC) for blood glucose &gt;140mg/dl was also significantly reduced (22.2&#177;16.4 vs. 41.1&#177;19.7mg/dlh, p&lt;0.05) with no difference in AUC for blood glucose &lt;70mg/dl (liraglutide 0.7&#177;0.9mg/dlh; placebo: 0.8&#177;1.4mg/dlh, p=NS). Finally, adding liraglutide reduced daily insulin requirement (37.5&#177;17.2 vs. 42.9&#177;22.4 UI/day, p&lt;0.01). Conclusions: Short-term treatment with liraglutide, in T1DM, reduces average blood glucose, blood glucose variability and daily insulin requirement without increasing risk of hypoglycemia. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper )
Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => STAMPA )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/pmid/26293127; info:eu-repo/semantics/altIdentifier/wos/WOS:000363950500014; volume:52; issue:6; firstpage:1129; lastpage:1133; numberofpages:5; journal:ACTA DIABETOLOGICA; http://hdl.handle.net/11568/763653; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84945461146; link.springer.de/link/service/journals/00592/index.htm )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1007/s00592-015-0800-6 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1007/s00592-015-0800-6&lt;br /&gt;http://hdl.handle.net/11568/763653 )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.470545AE )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1007/s00592-015-0800-6 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Continuous glucose monitoring [Type] => general ) [1] => Array ( [SubjectFull] => Glycemic variability [Type] => general ) [2] => Array ( [SubjectFull] => Insulin pump therapy [Type] => general ) [3] => Array ( [SubjectFull] => Liraglutide [Type] => general ) [4] => Array ( [SubjectFull] => Type 1 diabete [Type] => general ) [5] => Array ( [SubjectFull] => Adult [Type] => general ) [6] => Array ( [SubjectFull] => Aged [Type] => general ) [7] => Array ( [SubjectFull] => Area Under Curve [Type] => general ) [8] => Array ( [SubjectFull] => Blood Glucose [Type] => general ) [9] => Array ( [SubjectFull] => Body Mass Index [Type] => general ) [10] => Array ( [SubjectFull] => C-Peptide [Type] => general ) [11] => Array ( [SubjectFull] => Diabetes Mellitus [Type] => general ) [12] => Array ( [SubjectFull] => Type 1 [Type] => general ) [13] => Array ( [SubjectFull] => Female [Type] => general ) [14] => Array ( [SubjectFull] => Glucagon-Like Peptide-1 Receptor [Type] => general ) [15] => Array ( [SubjectFull] => Hemoglobin A [Type] => general ) [16] => Array ( [SubjectFull] => Glycosylated [Type] => general ) [17] => Array ( [SubjectFull] => Human [Type] => general ) [18] => Array ( [SubjectFull] => Hypoglycemia [Type] => general ) [19] => Array ( [SubjectFull] => Hypoglycemic Agent [Type] => general ) [20] => Array ( [SubjectFull] => Male [Type] => general ) [21] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [22] => Array ( [SubjectFull] => Endocrinology [Type] => general ) [23] => Array ( [SubjectFull] => Internal Medicine [Type] => general ) [24] => Array ( [SubjectFull] => Diabetes and Metabolism [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => CRISCI, ISABELLA ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Aragona, Michele ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Politi, Konstantina Savvina ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => DANIELE, GIUSEPPE ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => DEL PRATO, STEFANO ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Crisci, Isabella ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Aragona, Michele ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Politi, Konstantina Savvina ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Daniele, Giuseppe ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => DEL PRATO, Stefano ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2015 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) ) ) ) ) ) )
IllustrationInfo